[go: up one dir, main page]

MX2022004058A - Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo. - Google Patents

Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.

Info

Publication number
MX2022004058A
MX2022004058A MX2022004058A MX2022004058A MX2022004058A MX 2022004058 A MX2022004058 A MX 2022004058A MX 2022004058 A MX2022004058 A MX 2022004058A MX 2022004058 A MX2022004058 A MX 2022004058A MX 2022004058 A MX2022004058 A MX 2022004058A
Authority
MX
Mexico
Prior art keywords
kir3dl3
same
immune system
receptor inhibitor
antibody
Prior art date
Application number
MX2022004058A
Other languages
English (en)
Inventor
Xingxing Zang
Yao Wei
Xiaoxin Ren
Scott Moerdler
Original Assignee
Albert Einstein College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine filed Critical Albert Einstein College Medicine
Publication of MX2022004058A publication Critical patent/MX2022004058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se describen anticuerpos, fragmentos inmunogénicos y composiciones de los mismos dirigidos a la proteína receptora de tipo inmunoglobulina de células asesinas KIR3DL3, así como métodos de uso de los mismos para el tratamiento de enfermedades humanas, incluyendo el cáncer.
MX2022004058A 2019-10-04 2020-10-01 Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo. MX2022004058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962911169P 2019-10-04 2019-10-04
PCT/US2020/053857 WO2021067633A2 (en) 2019-10-04 2020-10-01 Kir3dl3 is an inhibitory receptor of the immune system and uses thereof

Publications (1)

Publication Number Publication Date
MX2022004058A true MX2022004058A (es) 2022-07-13

Family

ID=75338603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004058A MX2022004058A (es) 2019-10-04 2020-10-01 Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.

Country Status (11)

Country Link
US (1) US12534527B2 (es)
EP (1) EP4037712A4 (es)
JP (1) JP7638974B2 (es)
KR (1) KR20220075371A (es)
CN (1) CN114867493A (es)
AU (1) AU2020357889A1 (es)
BR (1) BR112022006177A2 (es)
CA (1) CA3153638A1 (es)
IL (1) IL291897A (es)
MX (1) MX2022004058A (es)
WO (1) WO2021067633A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4269434A1 (en) * 2020-12-23 2023-11-01 Guangdong Fapon Biopharma Inc. Anti-pd-l1 antibody and use thereof
JP2025506731A (ja) * 2022-02-22 2025-03-13 ネクストポイント セラピューティクス， インコーポレイテッド Ｋｉｒ３ｄｌ３阻害剤及び免疫細胞活性化剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1989002468A1 (en) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3418982B2 (ja) 1990-10-31 2003-06-23 ソマティクス セラピー コーポレイション 内皮細胞の遺伝的変性
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
BR112013005116A2 (pt) * 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
AU2012248158C1 (en) 2011-04-28 2017-02-02 Sbi Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase sigma antibody
WO2013095850A1 (en) 2011-12-20 2013-06-27 Dow Global Technologies Llc Methods for alcohol dehydration
DK2897980T3 (da) 2012-09-19 2020-02-17 Innate Pharma Kir3dl2-bindemidler
US10093737B2 (en) 2013-03-01 2018-10-09 Albert Einstein College Of Medicine, Inc. HHLA2 as a novel inhibitor of human immune system and uses thereof
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
CA2949947A1 (en) * 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway
EP3256157A4 (en) 2015-02-12 2018-08-01 The Regents of the University of Michigan Anti-kir antibodies
AU2018323955A1 (en) * 2017-08-30 2020-03-19 Phanes Therapeutics, Inc. Anti-LAG-3 antibodies and uses thereof
MX2020010094A (es) 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.

Also Published As

Publication number Publication date
IL291897A (en) 2022-06-01
WO2021067633A2 (en) 2021-04-08
US20230040568A1 (en) 2023-02-09
AU2020357889A1 (en) 2022-03-24
JP7638974B2 (ja) 2025-03-04
KR20220075371A (ko) 2022-06-08
WO2021067633A3 (en) 2021-05-14
EP4037712A4 (en) 2023-11-01
EP4037712A2 (en) 2022-08-10
US12534527B2 (en) 2026-01-27
CA3153638A1 (en) 2021-04-08
JP2022550468A (ja) 2022-12-01
BR112022006177A2 (pt) 2022-08-23
CN114867493A (zh) 2022-08-05

Similar Documents

Publication Publication Date Title
EA201892793A1 (ru) Анти-hla-g специфические антитела
MX2022002682A (es) Anticuerpos anti-cd73.
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201991005A1 (ru) Антитела и полипептиды, направленные против cd127
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
GT201200318A (es) Anticuerpos hacia gdf8 humano
UA109633C2 (uk) Антитіло людини проти тканинного фактора
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
EA202090372A1 (ru) Универсальные соединения авт и их применение
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
EA202091747A1 (ru) Составы антитела b7-h4
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
ZA202302392B (en) Antibodies against ilt2 and use thereof
ZA202008095B (en) Humanized antibodies against psma
EA202092518A1 (ru) Композиции и способы лечения рака
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2023011788A (es) Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
MX2022014736A (es) Anticuerpos anti-cd200r1 y metodos de uso de estos.
BR112022009482A2 (pt) Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.